Gemini Space Station Inc vs Illumina, Inc. — how do they compare? Gemini Space Station Inc trades at $4.46 (market cap $590.44M), while Illumina, Inc. trades at $189.3 (market cap $28.32B). The key difference: Illumina, Inc. is far larger — about 48× Gemini Space Station Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| GEMI | ILMN | |
|---|---|---|
Market Cap | $590.44M | $28.32B |
Sector | Technology | Health |
52-Week High | $32.52 | $194.33 |
52-Week Low | $3.91 | $91.00 |
Enterprise Value | $580.43M | $29.70B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.
The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.
Trailing returns across standard periods
Latest headlines on both assets
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →